Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia.

[1]  W. Abraham,et al.  Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. , 2012, Kidney international.

[2]  Warren Ho,et al.  Management of hyponatremia: Providing treatment and avoiding harm , 2010, Cleveland Clinic Journal of Medicine.

[3]  C. Thompson,et al.  The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. , 2010, European journal of endocrinology.

[4]  R. Schrier.  Does 'asymptomatic hyponatremia' exist? , 2010, Nature Reviews Nephrology.

[5]  S. Waikar,et al.  Mortality after hospitalization with mild, moderate, and severe hyponatremia. , 2009, The American journal of medicine.

[6]  D. Zygun,et al.  The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units , 2008, Critical care.

[7]  M. Konstam,et al.  Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia , 2008, Circulation.

[8]  C. Mélot,et al.  Mild hyponatremia and risk of fracture in the ambulatory elderly. , 2008, QJM : monthly journal of the Association of Physicians.

[9]  J. Verbalis,et al.  Hyponatremia treatment guidelines 2007: expert panel recommendations. , 2007, The American journal of medicine.

[10]  J. Verbalis,et al.  Assessment of the Efficacy and Safety of Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia , 2007, American Journal of Nephrology.

[11]  T. Berl,et al.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.

[12]  N. Madias,et al.  Incidence and prevalence of hyponatremia. , 2006, The American journal of medicine.

[13]  J. Ghali,et al.  Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. , 2006, The Journal of clinical endocrinology and metabolism.

[14]  W. Abraham,et al.  Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. , 2006, Journal of the American College of Cardiology.

[15]  R. Zietse,et al.  Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  M. Manto,et al.  Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. , 2006, The American journal of medicine.

[17]  J. Verbalis,et al.  Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia , 2004 .

[18]  R. Hawkins.  Age and gender as risk factors for hyponatremia and hypernatremia. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[19]  P. Thuluvath,et al.  A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial , 2003, Hepatology.

[20]  A. Patat,et al.  Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites , 2002, Hepatology.

[21]  J. Taylor,et al.  VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. , 1998, Advances in experimental medicine and biology.

[22]  L. Rubenstein,et al.  Hyponatremia in a Nursing Home Population , 1995, Journal of the American Geriatrics Society.

[23]  R. Anderson,et al.  Hospital-associated hyponatremia. , 1986, Kidney international.

[24]  M. Kleinfeld,et al.  Hyponatremia As Observed in a Chronic Disease Facility , 1979, Journal of the American Geriatrics Society.